Circulating isomiRs May Be Superior Biomarkers Compared to Their Corresponding miRNAs: A Pilot Biomarker Study of Using isomiR-Ome to Detect Coronary Calcium-Based Cardiovascular Risk in Patients with NAFLD.

NAFLD biomarker cardiovascular risk coronary artery calcium (CAC) score isomiR (iso-microRNA) microRNA

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
10 Jan 2024
Historique:
received: 19 11 2023
revised: 01 01 2024
accepted: 03 01 2024
medline: 23 1 2024
pubmed: 23 1 2024
entrez: 23 1 2024
Statut: epublish

Résumé

Circulating miRNAs are increasingly being considered as biomarkers in various medical contexts, but the value of analyzing isomiRs (isoforms of canonical miRNA sequences) has not frequently been assessed. Here we hypothesize that an in-depth analysis of the full circulating miRNA landscape could identify specific isomiRs that are stronger biomarkers, compared to their corresponding miRNA, for identifying increased CV risk in patients with non-alcoholic fatty liver disease (NAFLD)-a clinical unmet need. Plasma miRNAs were sequenced with next-generation sequencing (NGS). Liver fat content was measured with magnetic-resonance spectrometry (MRS); CV risk was determined, beyond using traditional biomarkers, by a CT-based measurement of coronary artery calcium (CAC) score and the calculation of a CAC score-based CV-risk percentile (CAC-CV%). This pilot study included n = 13 patients, age > 45 years, with an MRS-measured liver fat content of ≥5% (

Identifiants

pubmed: 38255963
pii: ijms25020890
doi: 10.3390/ijms25020890
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Israel Science Foundation
ID : 2176/19
Organisme : German Research Foundation, Grant/Award Numbers
ID : 209933838, SFB1052
Organisme : Obesity mechanisms
ID : project B2

Auteurs

Nataly Makarenkov (N)

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Department of Software & Information Systems Engineering, Faculty of Engineering, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Uri Yoel (U)

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
The Endocrinology Unit, Soroka University Medical Center, Beer-Sheva 84101, Israel.

Yulia Haim (Y)

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Yair Pincu (Y)

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Nikhil S Bhandarkar (NS)

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Aryeh Shalev (A)

Cardiology Department, Soroka University Medical Center, Beer-Sheva 84101, Israel.

Ilan Shelef (I)

Department of Diagnostic Imaging, Soroka University Medical Center, Beer-Sheva 84101, Israel.

Idit F Liberty (IF)

Diabetes Clinic, Soroka University Medical Center, Beer-Sheva 84101, Israel.

Gal Ben-Arie (G)

Department of Diagnostic Imaging, Soroka University Medical Center, Beer-Sheva 84101, Israel.

David Yardeni (D)

Department of Gastroenterology and Liver Diseases, Soroka University Medical Center, Beer-Sheva 84101, Israel.

Assaf Rudich (A)

Department of Clinical Biochemistry and Pharmacology, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Ohad Etzion (O)

Department of Gastroenterology and Liver Diseases, Soroka University Medical Center, Beer-Sheva 84101, Israel.

Isana Veksler-Lublinsky (I)

Department of Software & Information Systems Engineering, Faculty of Engineering, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.

Classifications MeSH